Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs (Q34541147)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

decision making

1 reference

based on heuristic

inferred from title

author name string

Anirban Basu

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Herbert Y Meltzer

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Journal of Comparative Effectiveness Research

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

171-180

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

The impact of comparative effectiveness research on health and health care spending

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Use of Antipsychotics Pre- and Post-Dissemination of CATIE Data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

What have we learned about trial design from NIMH-funded pragmatic trials?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Combination therapy in the treatment of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Clinical trials design lessons from the CATIE study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

The spurious advance of antipsychotic drug therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Pharmacogenetics and schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Heterogeneity of treatment effects in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Clinical trial-based cost-effectiveness analyses of antipsychotic use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Trends in prescription drug expenditures by Medicaid enrollees

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Transmission disequilibrium suggests a role for the sulfotransferase-4A1 gene in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Medicaid policies to contain psychiatric drug costs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Pharmacogenomics in schizophrenia: the quest for individualized therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Pharmacogenomics and schizophrenia: clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

7 July 2018

Atypical antipsychotic drugs have their merits

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.8

21 January 2018

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.8

21 January 2018

Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.8

21 January 2018

Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.8

21 January 2018

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.8

21 January 2018

Managing Psychotropic Drug Costs: Will Formularies Work?

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.8

21 January 2018

Benefit coverage of novel antipsychotics in Medicaid programs and the Veterans Health Administration

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.8

21 January 2018

Do new prescription drugs pay for themselves? The case of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.8

21 January 2018

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.8

21 January 2018

ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.8

21 January 2018

Future of individualized psychiatric treatment.

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.8

21 January 2018

Clinical practice variations in prescribing antipsychotics for patients with schizophrenia

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.8

21 January 2018

Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

27 October 2018

Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

27 October 2018

Interpreting the efficacy findings in the CATIE study: what clinicians should know.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237158

27 October 2018

Medicaid's prior authorization program and access to atypical antipsychotic medications

1 reference

https://pubmed.ncbi.nlm.nih.gov/24237376

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of schizophrenia pharmacotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24237376

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2217/CER.12.8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34541147&oldid=1961565370"